

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2025, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ATOPIC DERMATITIS	Adbry Autoinjector (tralokinumab)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANGIOTENSIN MODULATORS (ARB COMBINATIONS)	Entresto Sprinkle (sacubitril and valsartan)
ANTICHOLINERGICS & COPD AGENTS	Ohtuvayre (ensifentrine)
ANTICONVULSANTS (ADJUVANTS)	Vigafyde (vigabatrin)
ANTINEOPLASTICS	Retevmo (selpercatinib)
ANTINEOPLASTICS	Voranigo (vorasidenib)
BILE SALTS	Iqirvo (elafibranor)
BILE SALTS	Livdelzi (seladelpar lysine)
ERYTHROPOIESIS STIMULATING PROTEINS	Vafseo (vadadustat)
IMMUNE GLOBULINS	Alyglo (immune globulin)
SKELETAL MUSCLE RELAXANTS	Tanlor (methocarbamol)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



An Asterisk (*) denotes a new class added to the Preferred Drug List (PDL).

PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
ACNE AGENTS	adapalene gel; adapalene gel pump	X	
	isotretinoin capsule; clindamycin phosphate benzoyl peroxide gel (generic Onexton); sodium w/sulfur suspension 10-5%		X
ANALGESICS/ANESTHETICS	lidocaine-prilocaine cream	X	
	Lidocan II, III, IV, V, Tridacaine II, III, and DermacinRx Lidocan		X
ANALGESICS, OPIOIDS	Xtampza ER capsule	X	
ANDROGENIC AGENTS	testosterone pump; testosterone gel pump	X	
ANTIBIOTICS	Cleocin cream; Nuversa gel vancomycin solution	X	
	Firvanq solution; Clindesse cream; nitrofurantoin suspension		X
ANTICONVULSANTS	Trileptal suspension	X	
	oxcarbazepine suspension		X
ANTIDEPRESSANTS	vilazodone tablet	X	
	citalopram capsule; sertraline capsule; Viibryd tablet		X
ANTIEMETICS	Diclegis DR tablet	X	
ANTIFUNGALS	econazole cream; ketoconazole cream	X	
	Micotrin AC Cream; Mycozyl cream; Mycozyl powder; clotrimazole solution NDC 50228-0502-61; griseofulvin suspension		X
ANTIMIGRAINE AGENTS, CGRP ACUTE TREATMENT	Ubrelyv tablet	X	
ANTIPARASITICS (TOPICAL)	Vanalice gel	X	
ANTIPARKINSONS AGENTS	pramipexole tablet	X	
ANTIPSORIATICS (TOPICAL)*	calcipotriene cream; Enstilar foam; Taclonex ointment; Taclonex suspension	X	

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
ANTIVIRALS - ANTI-HERPETIC AGENTS	famciclovir tablet	X	
ATOPIC DERMATITIS	Eucrisa ointment	X	
BETA BLOCKERS, ANTIANGINALS & SINUS NODE AGENTS	Hemangeol solution	X	
BONE RESORPTION/SUPPRESSION & RELATED AGENTS	Forteo injection; raloxifene tablet	X	
BPH AGENTS	dutasteride capsule	X	
BRONCHODILATORS, BETA AGONIST	albuterol ER tablet		X
CEPHALOSPORINS AND RELATED ANTIBIOTICS	cefixime capsule	X	
	amoxicillin/clavulanate ER tablet		X
COLONY STIMULATING FACTORS	Fulphila injection	X	
	Stimufend injection; Fynetra injection		X
CYSTIC FIBROSIS AGENTS	Pulmozyme inhalation solution	X	
CYTOKINE & CAM ANTAGONISTS	Rinvoq (all formulations); Olumiant tablet	X	
FACTOR DEFICIENCY PRODUCTS	Altuviiio kit	X	
GENITAL WARTS & ACTINIC KERATOSIS AGENTS	fluorouracil cream	X	
GI ULCER THERAPIES	Carafate suspension	X	
	cimetidine suspension; sucralfate suspension		X
GROWTH HORMONE	Skytrofa injection	X	
	Nutropin injection		X
HEREDITARY ANGIOEDEMA	Berinert kit; icatibant injection; Haegarda	X	
HYPOGLYCEMICS, INSULINS AND RELATED AGENTS	Levemir (all formulations)		X
HYPOGLYCEMICS, SGLT2	Synjardy XR tablet; Glyxambi tablet; Trijardy XR tablet	X	
	Invokana tablet; Invokamet tablet		X

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
IBS/SBS/SELECTED GI AGENTS	lubiprostone capsule; Linzess (72 mcg) capsule; Trulance tablet	X	
	Amitiza capsule		X
LIPOTROPICS, OTHER (NON-STATINS)	colestipol packet; colestipol granule; fenofibrate capsule; fenofibric acid capsule	X	
	Praluent injection		X
MULTIPLE SCLEROSIS AGENTS	Gilenya capsule; Avonex injection		X
OPHTHALMIC, DRY EYE AGENTS	Xiidra drop	X	
OPHTHALMIC, GLAUCOMA AGENTS	dorzolamide/timolol droperette; brimonidine/timolol drop (generic Combigan)		X
OTIC ANTIBIOTICS	fluocinolone oil drop	X	
PARATHYROID AGENTS	cinacalcet tablet	X	
	Rocaltrol solution		X
POTASSIUM REMOVING AGENTS	SPS suspension	X	
SEDATIVE HYPNOTICS	ramelteon tablet; eszopiclone tablet	X	
	zolpidem capsule; flurazepam capsule		X
STERIODS (TOPICAL) LOW POTENCY	alclometasone cream/ointment; Derma-Smoothe-FS oil	X	
STERIODS (TOPICAL) MEDIUM POTENCY	fluticasone cream/ointment; mometasone solution	X	
STERIODS (TOPICAL) HIGH POTENCY	betamethasone dipropionate augmented cream/ augmented lotion/ointment; fluocinonide cream/emollient cream/gel/ointment/solution	X	
	amcinonide cream; triamcinolone aerosol		X
STERIODS (TOPICAL) VERY HIGH POTENCY	clobetasol emollient cream/ foam/gel/solution	X	
STIMULANTS AND RELATED AGENTS	methylphenidate solution; Qelbree capsule; Vyvanse capsule; Xyrem solution	X	

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
ULCERATIVE COLITIS and CROHNS AGENTS	mesalamine ER capsule (generic Apriso ER); Lialda DR tablet		X
UREA CYCLE DISORDERS*	Carbaglu dispersible tablet	X	

DRAFT